There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tarsus Pharmaceuticals (TARS – Research Report) and Intuitive Surgical (ISRG – Research Report) with bullish sentiments.
Tarsus Pharmaceuticals (TARS)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $70.00. The company’s shares closed last Friday at $18.51.
According to TipRanks.com, Dolezal is a 4-star analyst with an average return of 7.9% and a 43.1% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Avadel Pharmaceuticals, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Tarsus Pharmaceuticals is a Strong Buy with an average price target of $47.40, a 151.3% upside from current levels. In a report issued on June 15, Bank of America Securities also maintained a Buy rating on the stock with a $42.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Intuitive Surgical (ISRG)
BTIG analyst Ryan Zimmerman assigned a Buy rating to Intuitive Surgical today and set a price target of $326.00. The company’s shares closed last Friday at $329.36, close to its 52-week high of $333.14.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 12.7% and a 49.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Treace Medical Concepts, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intuitive Surgical with a $318.06 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TARS: